<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351299</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-001786, BWH</org_study_id>
    <nct_id>NCT00351299</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium</brief_title>
  <official_title>Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect -
      a sedative) is effective for the treatment of acute delirium
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium is a mental disturbance that causes people to be confused and restless for a period
      of time. We will compare dexmedetomidine to the traditional therapy for treatment of acute
      delirium. Dexmedetomidine does not affect breathing. The traditional drugs might make one
      sleepy and may slow down breathing. The traditional therapy in this institution for acute
      delirium is _the use of Haloperidol, and/or benzodiazepines. Haloperidol is an antipsychotic
      drug that has calming effect. Benzodiazepines are sedatives with calming
      effect.Dexmedetomidine is approved by the Food and drug Administration (FDA) to sedate
      patients on a breathing machine for 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of Delirium</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Resolution of delirium as defined by 2 consecutive negative CAM-ICU assessments.
The Confusion Assessment Method for the ICU (CAM-ICU). The CAM-ICU assesses the four features of delirium: feature 1 is an acute change in mental status or a fluctuating mental status, feature 2 is inattention, feature 3 is altered level of consciousness, and feature 4 is disorganized thinking.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Ventilator Support</measure>
    <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
    <description>Number of days on mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
    <description>Number of days intensive care unit (ICU) stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Management for the Nursing Staff</measure>
    <time_frame>Up to initial 48 hours</time_frame>
    <description>Subjective measure rating 3 categories for ease of management:
Mostly easy
Easy to manage 75% of the time
Not easy to manage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital Mortality</measure>
    <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
    <description>Did patient die while in the hospital? (Yes/No)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Delirium</condition>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>Infusion of dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion 0.3-0.7 dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care per treating physician preference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>dexmedetomidine infusion titrated to effect</description>
    <arm_group_label>Infusion of dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care per treating physician preference</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults admitted to our surgical ICU who do not have any exclusion criteria

          -  Eligibility for treatment- Development of delirium as defined

        Exclusion Criteria:

          -  Acute MI (myocardial infarction),

          -  Trauma &lt;24 hours,

          -  Head injury,

          -  Multiple organ failure,

          -  EF (ejection fraction) &lt; 30%,

          -  History of hypersensitivity to alpha2 agonist,

          -  History of seizures, MAP (mean arterial pressure) &lt;60 mm of Hg,

          -  Dysrhythmias a/with bradycardia (HR (heart rate) &lt;50),

          -  Need for vasopressors,

          -  Acute renal failure with a need for dialysis/CVVH (Continuous Veno-Venous
             Hemofiltration) or liver disease.

          -  Women of child bearing age who do not have a documented negative pregnancy test and/or
             who do not actively use contraception. (Documented negative pregnancy test will be a
             urine pregnancy test obtained on this admission)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald L Weinhouse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gerald L. Weinhouse</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>Agitation</keyword>
  <keyword>Sedation</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Surgical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients admitted to ICU from 2005-2008</recruitment_details>
      <pre_assignment_details>Patients enrolled and randomized upon admission to ICU but treated with dexmedetomidine or standard of caremodalities only if they developed delirium.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Infusion of Dexmedetomidine</title>
          <description>infusion 0.2-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Standard of care per treating physician preference</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infusion of Dexmedetomidine</title>
          <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Standard of care per treating physician preference</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.00" spread="10.36"/>
                    <measurement group_id="B2" value="63.93" spread="11.55"/>
                    <measurement group_id="B3" value="63.96" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resolution of Delirium</title>
        <description>Resolution of delirium as defined by 2 consecutive negative CAM-ICU assessments.
The Confusion Assessment Method for the ICU (CAM-ICU). The CAM-ICU assesses the four features of delirium: feature 1 is an acute change in mental status or a fluctuating mental status, feature 2 is inattention, feature 3 is altered level of consciousness, and feature 4 is disorganized thinking.</description>
        <time_frame>Up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Dexmedetomidine</title>
            <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Per treating attending physician preference</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Delirium</title>
          <description>Resolution of delirium as defined by 2 consecutive negative CAM-ICU assessments.
The Confusion Assessment Method for the ICU (CAM-ICU). The CAM-ICU assesses the four features of delirium: feature 1 is an acute change in mental status or a fluctuating mental status, feature 2 is inattention, feature 3 is altered level of consciousness, and feature 4 is disorganized thinking.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Ventilator Support</title>
        <description>Number of days on mechanical ventilation</description>
        <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Dexmedetomidine</title>
            <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Per treating physician preference</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Ventilator Support</title>
          <description>Number of days on mechanical ventilation</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.50" upper_limit="15.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <description>Number of days intensive care unit (ICU) stay</description>
        <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Dexmedetomidine</title>
            <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Per attending physician preference</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) Stay</title>
          <description>Number of days intensive care unit (ICU) stay</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="11"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Management for the Nursing Staff</title>
        <description>Subjective measure rating 3 categories for ease of management:
Mostly easy
Easy to manage 75% of the time
Not easy to manage</description>
        <time_frame>Up to initial 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Dexmedetomidine</title>
            <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care per attending physician's preference</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Management for the Nursing Staff</title>
          <description>Subjective measure rating 3 categories for ease of management:
Mostly easy
Easy to manage 75% of the time
Not easy to manage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mostly easy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Easy to manage 75% of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not easy to manage</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-hospital Mortality</title>
        <description>Did patient die while in the hospital? (Yes/No)</description>
        <time_frame>Patients will remain in the study for up to 7 days after development of delirium or discharge from ICU whichever is earlier, up to study end</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infusion of Dexmedetomidine</title>
            <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of Care Per treating physician's preference</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Mortality</title>
          <description>Did patient die while in the hospital? (Yes/No)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes, died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No, did not die</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infusion of Dexmedetomidine</title>
          <description>infusion 0.3-0.7 dexmedetomidine
Dexmedetomidine: dexmedetomidine infusion titrated to effect</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Standard of care per treating physician preference</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gerald Weinhouse</name_or_title>
      <organization>BrighamHospital</organization>
      <phone>617-732-5499</phone>
      <email>gweinhouse@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

